Introduction

Psoriasis is a chronic inflammatory skin disease with systemic implications, often associated with various comorbidities beyond the skin. Recent studies have revealed a potential link between psoriasis and neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), which has garnered increasing attention in dermatology and neurology. This review aims to summarize the current understanding of this association, the shared inflammatory and immunological mechanisms, and the clinical implications of these findings.

Epidemiological Evidence of Comorbidity

Large-scale population-based studies and meta-analyses have suggested a higher risk of developing neurodegenerative diseases among patients with psoriasis. For instance, psoriasis patients may have a significantly elevated risk of developing Alzheimer's disease and a moderately increased risk of Parkinson's disease. These findings point toward a shared pathophysiological basis that extends beyond coincidence.

Shared Inflammatory and Immune Mechanisms

Both psoriasis and neurodegenerative diseases involve chronic systemic inflammation. Psoriasis is characterized by excessive activation of Th1 and Th17 immune responses, leading to high levels of inflammatory cytokines such as TNF-α, IL-17, and IL-23. Interestingly, these cytokines are also implicated in the neuroinflammation observed in Alzheimer's and Parkinson's diseases. Elevated TNF-α and IL-17 have been detected in the brains of patients with AD and PD, suggesting that chronic inflammation in psoriasis could exacerbate neurodegeneration.

The Role of Oxidative Stress and the Blood-Brain Barrier

Oxidative stress and impaired blood-brain barrier (BBB) function are common features of both disease groups. Systemic inflammation in psoriasis may disrupt the BBB, allowing peripheral immune cells and cytokines to infiltrate the brain, thereby promoting neuronal injury. Additionally, oxidative stress in both psoriasis and neurodegenerative diseases can contribute to mitochondrial dysfunction and further neuronal damage.

Clinical Implications and Interdisciplinary Management

Recognizing the potential link between psoriasis and neurodegenerative diseases has important clinical implications. Dermatologists should monitor cognitive and neurological symptoms in patients with chronic psoriasis, especially older adults. Early identification and interdisciplinary management may help improve outcomes. Biologic therapies that target systemic inflammation, such as TNF inhibitors and IL-17 blockers, have shown promise not only in controlling psoriasis but also in reducing the risk of developing neurodegenerative conditions.

Established Treatment Options for Psoriasis

While the association between psoriasis and neurodegenerative diseases continues to be studied, effective management of psoriasis remains a crucial step in mitigating systemic inflammation and its possible neurological consequences.

Clinically validated treatment options include:

- Topical therapies: Mild psoriasis can often be managed with corticosteroids, vitamin D analogs (e.g., calcipotriol), or tar-based preparations.
- Systemic therapies: For more severe forms, systemic medications such as methotrexate, cyclosporine, or oral retinoids may be prescribed. In recent years, biologic agents targeting TNF-α, IL-17, or IL-23 have become the gold standard for moderate to severe psoriasis, offering both skin clearance and systemic control.
- Phototherapy: Among non-systemic options, narrowband UVB (NB-UVB) phototherapy has shown high efficacy and safety for chronic plaque psoriasis. By modulating immune responses in the skin without systemic immunosuppression, UVB phototherapy presents a compelling option—especially for patients with contraindications to systemic agents.

Devices like the KernelMed KN-4006B UV Phototherapy Unit are specifically designed to deliver precise NB-UVB light wavelengths, making them ideal for clinical or home-based treatment. KernelMed’s phototherapy series offers safe, portable, and user-friendly technology for effective psoriasis management.

Early and targeted intervention using these therapies can not only alleviate skin symptoms but may also contribute to lowering systemic inflammation, potentially reducing the risk of cognitive decline in psoriasis patients.

Future Directions

Further research is needed to clarify the causal relationship between psoriasis and neurodegenerative diseases, and to explore whether systemic anti-inflammatory treatments can prevent or delay cognitive decline. Studies on the skin-brain axis, neuroimmunology, and longitudinal cohort analyses will provide valuable insights into shared mechanisms and therapeutic strategies.

Conclusion

The growing body of evidence linking psoriasis with neurodegenerative diseases underscores the importance of viewing psoriasis as a systemic disease with potential neurological consequences. While more research is needed, integrated treatment approaches—including biologic agents and UV phototherapy—may not only improve skin health but also help in reducing systemic inflammatory burdens. With advanced solutions such as those offered by KernelMed, clinicians and patients are better equipped to manage psoriasis comprehensively, potentially benefiting both skin and brain health.

References (APA Style)

1. 1.Charoenngam, N., Shirvani, A., Kalapatapu, V., & Holick, M. F. (2020). Association between psoriasis and risk of Alzheimer’s disease and dementia: A systematic review and meta-analysis. Journal of Clinical Medicine, 9(5), 1533. https://doi.org/10.3390/jcm9051533

2. 2.Pei, X. C., Yu, Q., & Zhu, C. (2021). Association between psoriasis and Parkinson's disease: A meta-analysis. Neuropsychiatric Disease and Treatment, 17, 1145–1151. https://doi.org/10.2147/NDT.S308529

3. 3.Ungprasert, P., Wijarnpreecha, K., & Thongprayoon, C. (2016). Psoriasis and risk of Parkinson’s disease: A systematic review and meta-analysis. Neurological Sciences, 37(4), 573–577. https://doi.org/10.1007/s10072-015-2423-3

4. 4.Li, Y., Yang, Y., Li, X., Zhang, Y., & Wu, Q. (2022). Causal association between psoriasis and Parkinson's disease: A Mendelian randomization study. Frontiers in Genetics, 13, 923457. https://doi.org/10.3389/fgene.2022.923457

5. 5.Islam, M. M., Poly, T. N., Yang, H. C., Wu, C. C., Li, Y. C., & Nguyen, P. A. (2019). Association between psoriasis and multiple sclerosis: A systematic review and meta-analysis. EClinicalMedicine, 7, 11–20. https://doi.org/10.1016/j.eclinm.2019.01.004

6. 6.Liu, Y., Wang, L., & Wang, J. (2022). Risk of psoriasis in patients with multiple sclerosis: A systematic review and meta-analysis. Frontiers in Neurology, 13, 847465. https://doi.org/10.3389/fneur.2022.847465

7. 7.Jansen, I. E., Savage, J. E., Watanabe, K., Bryois, J., Williams, D. M., Steinberg, S., ... & Posthuma, D. (2019). Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nature Genetics, 51(3), 404–413. https://doi.org/10.1038/s41588-018-0311-9

8. 8.Ellis, C. N., & Krueger, G. G. (2001). Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. New England Journal of Medicine, 345(4), 248–255. https://doi.org/10.1056/NEJM200107263450405

9. 9.Cheng, X., He, P., & Ma, J. (2014). Triptolide ameliorates Alzheimer’s disease-related pathologies and cognitive impairments in APP/PS1 transgenic mice. Current Alzheimer Research, 11(3), 290–299. https://doi.org/10.2174/15672050113106660071

10. 10.Chen, Y., & Colonna, M. (2021). IL-23, not IL-12, directs autoimmunity in a model of multiple sclerosis. Science, 294(5540), 1736–1739. https://doi.org/10.1126/science.1063563

11. Magnano, M., Balestri, R., Bardazzi, F., et al. (2014). Psoriasis and multiple sclerosis: A possible pathogenic association. Dermatology Reports, 6(4), 5463. https://doi.org/10.4081/dr.2014.5463

12. 11.Seror, R., Richez, C., Sordet, C., et al. (2013). Pattern of demyelination occurring during anti-TNF-α therapy: A French national survey. RMD Open, 72(5), 761–767. https://doi.org/10.1136/annrheumdis-2012-201631

13. 12.Piaserico, S., Cazzaniga, S., Yiu, Z. Z., Naldi, L., & Griffiths, C. E. M. (2020). Incidence of neurological adverse events in patients with psoriasis treated with biologics: A cohort study. British Journal of Dermatology, 183(3), 568–575. https://doi.org/10.1111/bjd.18791

14. 13.Armstrong, A. W., Harskamp, C. T., & Armstrong, E. J. (2013). Psoriasis and the risk of diabetes mellitus: A systematic review and meta-analysis. JAMA Dermatology, 149(1), 84–91. https://doi.org/10.1001/jamadermatol.2013.3023

15. 14.Gelfand, J. M., Mehta, N. N., & Langan, S. M. (2011). Psoriasis and cardiovascular risk: Strength in numbers. JAMA, 306(7), 756–758. https://doi.org/10.1001/jama.2011.1101